Understanding Androgenetic Alopecia: Key Information

Clinical Overview

Androgenetic alopecia (AGA), commonly known as male-pattern baldness or female-pattern baldness, is the most prevalent form of hair loss in humans, accounting for approximately 50% of all hair loss in men by age 50 and affecting 40% of women by age 50. This condition results from genetic predisposition combined with hormonal sensitivity to androgens, particularly dihydrotestosterone (DHT), and causes progressive miniaturization of terminal hairs on the scalp.

Epidemiology

Male-pattern baldness affects over 50 million men in the United States, with prevalence increasing with age. By age 35, approximately 40% of men experience some degree of hair loss; by age 50, this increases to 50%. Female-pattern hair loss affects approximately 30% of women by age 50 and 50% by age 80. The condition shows autosomal dominant inheritance with incomplete penetrance, meaning multiple family members may be affected. Caucasian men show highest prevalence, followed by Hispanic, African, and Asian populations respectively.

Pathophysiology

Androgenetic alopecia results from miniaturization of hair follicles in genetically predisposed individuals. The 5-alpha reductase enzyme converts testosterone to DHT, the more potent androgen. In scalp follicles of susceptible individuals, DHT binds to androgen receptors in dermal papilla cells, shortening the anagen (growth) phase from 2-6 years to weeks or months. Simultaneously, the catagen (transition) and telogen (resting) phases lengthen, and follicles progressively shrink, producing finer hairs. Over time, terminal hairs (thick pigmented hairs) are replaced by vellus hairs (fine, nearly colorless hairs), creating the appearance of baldness even when follicles remain present.

Clinical Presentation

Male-pattern baldness typically begins with bitemporal recession or crown thinning. The Norwood scale, ranging from I (normal) to VII (extensive baldness), helps classify severity. Women typically experience diffuse vertex or crown thinning while preserving the frontal hairline—a pattern classified by the Ludwig scale from I (no visible hair loss) to III (pronounced hair loss with sparse or absent central hair). Patients report gradual hair loss over months to years, increased hair shedding during shampooing or brushing, and progressive widening of the part line. Unlike alopecia areata or scarring alopecias, scalp inflammation or physical symptoms are absent. Hair loss typically begins in the 20s-30s but can start in the teenage years.

Diagnosis

Diagnosis is primarily clinical based on history and physical examination. The pull test, performed by gently pulling 60 hairs, should yield fewer than 6 hairs; more than 6 suggests concurrent telogen effluvium. Dermoscopy may reveal reduced hair density, increased follicular spacing, and mixed diameter hairs. Scalp biopsy is rarely needed unless the diagnosis is uncertain or atypical features suggest alternative diagnoses. Patients should be assessed for anemia, thyroid dysfunction, and nutritional deficiencies (iron, zinc, protein, vitamin D, vitamin B12), as these treatable conditions may contribute to hair loss. A careful family history establishes genetic predisposition.

Treatment Algorithm

First-line treatments for male-pattern baldness include topical minoxidil (5% foam or 2% solution) applied twice daily to the scalp, and oral finasteride (Propecia) 1 mg daily. The Olsen et al. 2002 study in the Journal of the American Academy of Dermatology demonstrated that 48% of men receiving finasteride 1 mg daily experienced moderate to dense regrowth, 42% maintained their baseline hair count, and only 10% experienced continued hair loss. Minoxidil showed similar efficacy with approximately 45% achieving moderate regrowth. Combination therapy (minoxidil plus finasteride) demonstrates superior efficacy compared to monotherapy, with response rates of 60-65% achieving measurable regrowth.

Dutasteride (Avodart) 0.5 mg daily, a dual 5-alpha reductase inhibitor, is more potent than finasteride but is not FDA-approved for hair loss (though used off-label). Topical treatments offer alternatives: topical finasteride 0.1% solution and topical dutasteride 0.1% are under investigation and may reduce systemic side effects. Low-level laser therapy (LLLT) devices operating at 655-1000 nm wavelengths and delivering 10-100 mW/cm2 have shown modest efficacy (20-30% hair count increase) in some studies but lack consistent evidence.

For female-pattern hair loss, minoxidil 2% or 5% remains first-line, with studies showing 40% of women achieving moderate regrowth. Finasteride is less effective in women unless they are post-menopausal, as it does not block ovarian androgen production. Spironolactone (Aldactone), a potassium-sparing diuretic with anti-androgenic properties, at doses of 100-200 mg daily offers benefit in women, with approximately 44% achieving moderate to dense regrowth in published series. This medication requires baseline potassium and creatinine assessment and periodic monitoring.

Hair transplantation using follicular unit extraction (FUE) or follicular unit transplantation (FUT) provides permanent surgical restoration. The Bernstein et al. 2006 study documented that FUE techniques achieve 90% graft survival rate with natural-appearing results when performed by experienced surgeons. Platelet-rich plasma (PRP) therapy, though popular, lacks robust evidence; meta-analyses show mixed results with response rates varying from 25-75% depending on protocol, suggesting heterogeneous quality across studies.

Prognosis

Without treatment, male-pattern baldness typically progresses to Norwood stage VI-VII over 20-30 years. Early intervention with finasteride or minoxidil slows progression and may halt hair loss in 50-60% of patients. With combination therapy, approximately 65-75% of patients maintain or improve hair density over 5-year treatment periods. Women generally have better prognosis with earlier intervention. Importantly, these medications require ongoing use—discontinuation typically results in return of hair loss within 6-12 months as miniaturization resumes.

When to See a Dermatologist

Consult a dermatologist if experiencing progressive hair loss, sudden onset hair shedding, or symptoms concerning for alternative diagnoses (scalp inflammation, scarring, patches of alopecia). Dermatologists can confirm diagnosis, assess for contributing systemic factors, and optimize treatment selection. Women with hair loss should be evaluated for hyperandrogenism (elevated androgen levels), as this may indicate underlying polycystic ovary syndrome or other endocrine disorders.

Frequently Asked Questions

Will minoxidil work if finasteride did not? Yes. Approximately 20-30% of patients who fail to respond to finasteride alone respond to minoxidil monotherapy or combination therapy, as these medications work through different mechanisms. Finasteride blocks DHT production while minoxidil improves follicle blood flow and extends anagen phase.

How long before seeing results from treatment? Finasteride typically requires 3-6 months to show benefit, and optimal response may take 12-24 months. Minoxidil shows response by 4-6 months in most patients. Premature discontinuation before 6 months is a common reason for treatment failure.

Can hair transplants treat extensive baldness? Hair transplants work best for localized baldness (Norwood stages I-IV). Extensive baldness (stage V-VII) may require multiple sessions or hybrid approaches combining medical therapy with transplantation. Limited donor hair restricts total grafts available.

Does finasteride cause permanent sexual dysfunction? Finasteride causes sexual side effects in approximately 1-3% of users—rates similar to placebo in controlled trials. The overwhelming majority of users experience no sexual dysfunction. Post-finasteride syndrome (persistent sexual dysfunction after discontinuation) is rare and lacks mechanism of action.

References